PPIRE12793
Target Protein Information
| Protein_Name | DNA repair protein RAD51 homolog 1 |
|---|---|
| Protein_Sequence | MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD |
| Organism_Source | Homo sapiens |
| Functional_Classification | recombinase |
| Cellular_Localization | Nucleus |
| Gene_Names | RAD51 |
| UniProt_ID | Q06609 |
| Protein-Protein Interaction Networks | |
Peptide Basic Information
| Peptide_Name | BRCA1(854-871) |
|---|---|
| Peptide_Sequence | AQYLQNTFKVSKRQSFAP |
| Peptide_Length | 18 |
| Peptide_SMILES | CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)[C@@H](C)O |
| Chemical_Modification | None |
| Cyclization_Method | None |
| Linear/Cyclic | Linear |
| N-terminal_Modification | Acetyl |
| C-terminal_Modification | amide |
| Amino_Acid_Distribution | |
|
|
|
Peptide Physicochemical
| Molecular_Weight | 2113.40 |
|---|---|
| Aliphatic_Index | 48.88889 |
| Aromaticity | 0.16667 |
| Average_Rotatable_Bonds | 3.83333 |
| Charge_at_pH_7 | 2.99654 |
| Isoelectric_Point | 10.90181 |
|---|---|
| Number_of_Hydrogen_Bond_Acceptors | 30 |
| Number_of_Hydrogen_Bond_Donors | 31 |
| Topological_Polar_Surface_Area | 916.45000 |
| X_logP_energy | -10.11973 |
Interaction Information
| Affinity | KD=126.44 uM |
|---|---|
| Affinity_Assay | MicroScale Thermophoresis |
| PDB_ID | None |
| Type | Inhibitor |
| Structure | |
Reference Information
| Document_Type | Research Articles |
|---|---|
| Title | Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. |
| Release_Year | 2019 |
| PMID | None |
| DOI | 10.1007/s10989-019-09821-7 |